3B BlackBio Dx Reports Strong Q2 FY27 Results Driven by Diagnostic Growth
3B BlackBio Dx Ltd · Financial Result · 13 Nov 2026, 10:27 pm
3B BlackBio Dx Reports Strong Q2 FY27 Results Driven by Diagnostic Growth For Q2 ended 30th Sep'26, 3B BlackBio Dx posted consolidated revenue from operations of ₹4,828.02 lakh, surging 42.4% YoY and 44.2% QoQ. Net profit rose 19.9% YoY and 100.7% QoQ to ₹1,802.33 lakh, with EPS at ₹21.03. Growth was led by Diagnostic Kits, delivering revenue of ₹4,502.48 lakh (up 48.0% YoY) and segment EBIT of ₹2,442.46 lakh, while Agrochemicals posted a slight EBIT loss of ₹6.82 lakh. For H1 ended 30th Sep'26, consolidated revenue reached ₹8,177.10 lakh with a net profit of ₹2,700.17 lakh.
Original exchange filing (PDF)
More announcements from 3B BlackBio Dx Ltd
- Analyst/Investor Meet intimation · 16 Nov 2026
- Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- Investor Presentation · 13 Nov 2026
- Financial Results for the quarter and half-year ended 30th September, 2026 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- 3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Unaudited Standalone and .... · 13 Nov 2026
- Re-appointment of director who retires by rotation and being eligible, offers for re-appointment · 30 Sept 2026
- Scrutinizer''s Report and Voting report for 54th AGM · 30 Sept 2026
